Current guidelines [13] recommend that acidosis and metabolic bone disease be treated and nutritional deficiencies be corrected and if growth velocity or height SDS score remains abnormal, treatment with recombinant GH should be considered. This evidence concerns the gene GH1 and hyperinsulinemic hypoglycemia, familial, 4.